Is It Too Late To Consider Pharvaris (PHVS) After A 3.5x Three Year Surge?

Simply Wall St.03-23

If you are wondering whether Pharvaris at around US$26 a share still offers value, it helps to step back and look at what the recent returns and current valuation are really telling you. The stock has...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621764744?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-03-23 06:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621764744","market":"hk","top_or_hot":-1,"title":"Is It Too Late To Consider Pharvaris (PHVS) After A 3.5x Three Year Surge?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Pharvaris at around US$26 a share still offers value, it helps to step back and look at what the recent returns and current valuation are really telling you. The stock has...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/is-it-too-late-to-consider-pharvaris-phvs-after-a-35x-three\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late To Consider Pharvaris (PHVS) After A 3.5x Three Year Surge?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late To Consider Pharvaris (PHVS) After A 3.5x Three Year Surge?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-23 06:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/is-it-too-late-to-consider-pharvaris-phvs-after-a-35x-three><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Pharvaris at around US$26 a share still offers value, it helps to step back and look at what the recent returns and current valuation are really telling you. The stock has...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/is-it-too-late-to-consider-pharvaris-phvs-after-a-35x-three\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/is-it-too-late-to-consider-pharvaris-phvs-after-a-35x-three","article_id":"2621764744","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/is-it-too-late-to-consider-pharvaris-phvs-after-a-35x-three","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621764744","pubTimestamp":1774217454,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Pharvaris at around US$26 a share still offers value, it helps to step back and look at what the recent returns and current valuation are really telling you.\nThe stock has delivered a 68.8% return over the past year and a very large 3 year gain of around 3.5x, even though the year to date return is a 1.8% decline and the 30 day return is a 7.5% decline. This can change how the risk and reward balance feels right now.\nRecent headlines around Pharvaris have focused...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PHVS":"Pharvaris N.V.","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"在Pharvaris(PHVS)三年飙升3.5倍后，现在考虑是否为时已晚？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHVS":1.5,"DCF":1},"content_text":"If you are wondering whether Pharvaris at around US$26 a share still offers value, it helps to step back and look at what the recent returns and current valuation are really telling you. The stock has delivered a 68.8% return over the past year and a very large 3 year gain of around 3.5x, even though the year to date return is a 1.8% decline and the 30 day return is a 7.5% decline. This can change how the risk and reward balance feels right now. Recent headlines around Pharvaris have focused on its position in the pharmaceuticals and biotech space, putting a spotlight on how the company is being priced compared with peers and the broader market. This mix of attention and past share price moves gives useful context for judging whether the current level makes sense. Pharvaris currently has a valuation score of 2 out of 6, which means it screens as undervalued on only some of the checks investors often watch. The next sections will walk through those methods before finishing with a broader way to think about what the valuation really implies.  Pharvaris scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Pharvaris Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model takes estimates of the cash a business might generate in the future, then discounts those cash flows back to today to arrive at an estimated intrinsic value per share. For Pharvaris, the latest twelve month free cash flow is a loss of about €134.4 million. Analysts provide explicit free cash flow estimates for the next few years, and Simply Wall St then extrapolates these further out. Under this 2 Stage Free Cash Flow to Equity model, free cash flow is projected to reach about €204.8 million in 2030, with additional extrapolated estimates extending to 2035. Bringing all those projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of about €331.63 per share. Compared with the current Nasdaq listing price, this suggests the shares trade at a 92.2% discount to this estimated value according to this approach. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Pharvaris is undervalued by 92.2%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks. PHVS Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Pharvaris. Approach 2: Pharvaris Price vs Book For companies that are still working toward sustained profitability, price-based multiples that rely less on current earnings, such as price to book, can be more useful than P/E. P/B compares the market value of the equity with the accounting value of net assets, which gives you a rough sense of how confidently the market is pricing the balance sheet. What counts as a “normal” or “fair” multiple is partly about what investors expect for growth and how much risk they see. Higher growth and lower perceived risk often line up with a higher multiple, while slower growth or higher uncertainty can justify a lower one. Pharvaris currently trades at a P/B of 4.68x. That sits above the pharmaceuticals industry average of 2.01x and also above the peer group average of 2.43x. Simply Wall St’s Fair Ratio is a proprietary estimate of what the P/B multiple could be given factors such as earnings growth profile, profit margins, industry, market cap and risk characteristics. Because it blends these company-specific inputs, it can be more tailored than a simple comparison with broad industry or peer averages. In this case, the Fair Ratio is not available, so a conclusion on whether the shares look overvalued or undervalued using this method is not provided. Result: ABOUT RIGHT NasdaqGS:PHVS P/B Ratio as at Mar 2026 P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies. Upgrade Your Decision Making: Choose your Pharvaris Narrative Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are worth getting to know because they let you attach a clear story about Pharvaris to the numbers you care about, such as your fair value, revenue, earnings and margin estimates. A Narrative links how you see the company’s opportunity and risks to a specific financial forecast and then to a fair value per share, so you are not just looking at ratios in isolation. On Simply Wall St’s Community page, used by millions of investors, Narratives are set up so you can quickly compare a Fair Value with the current share price, see whether that points you toward a particular stance on the stock, and have that view automatically refreshed when new news or earnings are added. For Pharvaris, one investor might set a relatively low fair value and cautious revenue and margin assumptions, while another might use a much higher fair value with more optimistic assumptions, and Narratives simply make those different views visible and comparable in one place. Do you think there's more to the story for Pharvaris? Head over to our Community to see what others are saying! NasdaqGS:PHVS 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621764744","isCrawlerRequest":true}